Plasma and dietary carotenoids are associated with reduced oxidative stress in women previously treated for breast cancer

Dietary patterns, risk and prognosis of breast cancer

Survival in women diagnosed with early-stage, invasive breast cancer has improved dramatically in the past 10–15 years. This is largely due to the use of pharmacological therapies targeting a reduction in estrogen action and exposure. Women diagnosed with breast cancer often alter their eating behavior towards healthier food choices in an attempt to improve their survival and their overall health and well being. Mounting interest in the role of diet to modify breast cancer survival and/or comorbidity and mortality has led researchers to evaluate the effects of differential dietary patterns on this disease. Current findings suggest a possible, but inconsistent, benefit of a prudent, vegetable-rich, low-fat/high-vegetable eating pattern on disease-free survival, but the results to date are limited by strong treatment effectiveness and low overall recurrence rates. It is more likely this prudent eating pattern will improve non-breast cancer mortality (e.g., cardiovascular disease) compared with a Western dietary pattern. Efforts to educate women diagnosed with breast cancer to consume a diet lower in total and saturated fat, higher in vegetables and fiber, and which results in mild to modest weight loss among overweight/obese women is sensible in light of the high survivability of breast cancer and need to direct attention to comorbidities that likely increase as a consequence of treatment and treatment-related weight gain and sedentary behavior. Additional research is needed to address the importance of diet in the breast cancer patient, particularly in relation to the effect of select dietary patterns on factors that influence individual recurrence risk (e.g., hormone levels, drug metabolism and oxidative stress), as well as factors that influence non-breast cancer morbidity risk and causes of death in the survivor population.

The carotenoid beta-cryptoxanthin stimulates the repair of DNA oxidation damage in addition to acting as an antioxidant in human cells

The role of dietary antioxidants in human health remains controversial. Fruits and vegetables in the diet are associated with lower rates of chronic disease, and this is often attributed to their content of antioxidants, and a resulting protection against oxidative stress. However, large-scale human trials with antioxidant supplements have shown, if anything, an increase in mortality. We have investigated the biological properties of beta-cryptoxanthin, a common carotenoid, in cell culture model systems, using the comet assay to measure DNA damage. At low concentrations, close to those found in plasma, beta-cryptoxanthin does not itself cause damage, but protects transformed human cells (HeLa and Caco-2) from damage induced by H(2)O(2) or by visible light in the presence of a photosensitizer. In addition, it has a striking effect on DNA repair, measured in different ways. Incubation of H(2)O(2)-treated cells with beta-cryptoxanthin led to a doubling of the rate of rejoining of strand breaks and had a similar effect on the rate of removal of oxidized purines by base excision repair. The latter effect was confirmed with an in vitro assay: cells were incubated with or without beta-cryptoxanthin before preparing an extract, which was then incubated with substrate DNA containing 8-oxo-7,8-dihydroguanine; incision was more rapid with the extract prepared from carotenoid-preincubated cells. No significant increases were seen in protein content of human 8-oxoguanine DNA glycosylase 1 or apurinic endonuclease 1. The apparent cancer-preventive effects of dietary carotenoids may depend on the enhancement of DNA repair as well as antioxidant protection against damage.

Modulation of gene methylation by genistein or lycopene in breast cancer cells

Dietary agents with chemopreventive potential, including soy-derived genistein and tomato-derived lycopene, have been shown to alter gene expression in ways that can either promote or potentially inhibit the carcinogenic processes. To begin to explore the mechanisms by which these agents may be acting we have examined the DNA methylation modulating capacity of genistein or lycopene for several genes relevant to breast cancer in the breast cancer cell lines MCF-7 and MDA-MB-468, as well as in immortalized but noncancer fibrocystic MCF10A breast cells. We find using methylation specific PCR (MSP) that a low, nontoxic concentration of genistein (3.125 microM, resupplemented every 48 hr for 1 week) or a single dose of lycopene (2 microM) partially demethylates the promoter of the GSTP1 tumor suppressor gene in MDA-MB-468 cells. RT-PCR studies confirm a lack of GSTP1 expression in untreated MDA-MB-468, with restoration of GSTP1 expression after genistein or lycopene treatment. The RARbeta2 gene however, was not demethylated by genistein or lycopene in either of these breast cancer cell lines. But, lycopene (2 microM, once per week for 2 weeks) did induce demethylation of RARbeta2 and the HIN-1 genes in the noncancer MCF10A fibrocystic breast cells. These data show for the first time that the tomato carotenoid lycopene has direct DNA demethylating activity. In summary, both genistein and lycopene, at very low, dietarily relevant concentrations can potentially mitigate tumorigenic processes via promoter methylation modulation of gene expression.